Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Assets (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Other Non-Current Assets for 10 consecutive years, with $482000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 8.88% to $482000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $482000.0 through Dec 2025, down 8.88% year-over-year, with the annual reading at $482000.0 for FY2025, 8.88% down from the prior year.
  • Other Non-Current Assets hit $482000.0 in Q4 2025 for Rocket Pharmaceuticals, down from $515000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $608000.0 in Q4 2022 to a low of $455000.0 in Q1 2021.
  • Historically, Other Non-Current Assets has averaged $497050.0 across 5 years, with a median of $492500.0 in 2024.
  • Biggest five-year swings in Other Non-Current Assets: surged 33.63% in 2022 and later fell 12.34% in 2023.
  • Year by year, Other Non-Current Assets stood at $455000.0 in 2021, then surged by 33.63% to $608000.0 in 2022, then dropped by 12.34% to $533000.0 in 2023, then decreased by 0.75% to $529000.0 in 2024, then fell by 8.88% to $482000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for RCKT at $482000.0 in Q4 2025, $515000.0 in Q3 2025, and $515000.0 in Q2 2025.